Chongqing Pharscin Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Chongqing Pharscin Pharmaceutical's earnings have been declining at an average annual rate of -24.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 3.3% per year. Chongqing Pharscin Pharmaceutical's return on equity is 3.8%, and it has net margins of 7.9%.
Belangrijke informatie
-24.1%
Groei van de winst
-24.8%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | -3.3% |
| Rendement op eigen vermogen | 3.8% |
| Nettomarge | 7.9% |
| Laatste winstupdate | 30 Sep 2024 |
Opbrengsten en kosten
Hoe Chongqing Pharscin Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 791 | 63 | 306 | 68 |
| 30 Jun 24 | 749 | 39 | 293 | 75 |
| 31 Mar 24 | 732 | 43 | 282 | 77 |
| 31 Dec 23 | 692 | 33 | 262 | 78 |
| 30 Sep 23 | 739 | 70 | 283 | 69 |
| 30 Jun 23 | 778 | 88 | 301 | 67 |
| 31 Mar 23 | 770 | 99 | 294 | 64 |
| 01 Jan 23 | 785 | 98 | 296 | 59 |
| 30 Sep 22 | 762 | 75 | 293 | 55 |
| 30 Jun 22 | 778 | 87 | 287 | 46 |
| 31 Mar 22 | 819 | 85 | 297 | 44 |
| 01 Jan 22 | 846 | 92 | 297 | 42 |
| 30 Sep 21 | 903 | 114 | 284 | 39 |
| 30 Jun 21 | 939 | 113 | 282 | 40 |
| 31 Mar 21 | 942 | 128 | 273 | 38 |
| 31 Dec 20 | 882 | 119 | 268 | 36 |
| 30 Sep 20 | 840 | 127 | 282 | 33 |
| 30 Jun 20 | 816 | 140 | 297 | 30 |
| 31 Mar 20 | 821 | 166 | 315 | 24 |
| 31 Dec 19 | 842 | 170 | 334 | 26 |
| 30 Sep 19 | 796 | 163 | 331 | 22 |
| 30 Jun 19 | 756 | 167 | 327 | 18 |
| 31 Mar 19 | 730 | 139 | 323 | 20 |
| 31 Dec 18 | 703 | 137 | 316 | 15 |
| 30 Sep 18 | 686 | 131 | 309 | 13 |
| 30 Jun 18 | 661 | 128 | 293 | 15 |
| 31 Mar 18 | 631 | 120 | 288 | 10 |
| 31 Dec 17 | 592 | 112 | 270 | 9 |
| 30 Sep 17 | 602 | 112 | 268 | 4 |
| 31 Dec 16 | 552 | 96 | 249 | 0 |
| 31 Dec 15 | 469 | 74 | 205 | 0 |
| 31 Dec 14 | 426 | 59 | 203 | 0 |
Kwaliteitswinsten: 002907 has high quality earnings.
Groeiende winstmarge: 002907's current net profit margins (7.9%) are lower than last year (9.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002907's earnings have declined by 24.1% per year over the past 5 years.
Versnelling van de groei: 002907's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 002907 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 002907's Return on Equity (3.8%) is considered low.